Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Cancer Lett. 2019 Mar 6;452:79–89. doi: 10.1016/j.canlet.2019.02.044

Figure 6. Autocrine TGF-β1/DNMT3B/miR-141 axis enhances TCF12 in CAFs to promote breast cancer cell proliferation.

Figure 6.

(A-B) The percentages of S-phase cells in cell cycle are shown by histogram in the MCF-7 (A) or MDA-MB-231 (B) cells co-cultured with supernatant from indicated fibroblasts. The labeled number represents the percent of cells in S-phase. Exo R, exosome were eliminated from the supernetant of fibroblasts by centrifugation. 5′-AZA, 5-aza-2′-deoxycytidine. Error bars, SD (n=3).

(C) Western blot analysis of TCF12 in TGF-β1 activated NFs and CAFs treated with TGF-β1 neutralized antibody (α-TGF-β1) or SB431542.

(D) Western blot analysis of DNMT3B and TCF12 in CAF/sh-DMT3b #1 and CAF/sh-DNMT3B #2, and NF/DNMT3B.

(E-F) The percentages of S-phase cells in cell cycle are shown by histogram in the indicated breast cancer cells co-cultured with supernatant from CAF/sh-TCF12 treated with miR-141 mimics (E) or co-cultured with supernatant from NF/TCF12 treated with miR-141 inhibitors (F). The labeled number represents the percent of cells in S-phase. Error bars, SD (n=3).